Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2024
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
Would you offer adjuvant endocrine therapy to a patient with a history of ER-positive DCIS, s/p bilateral mastectomy, now with chest wall recurrence of DCIS four year later?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
How would you treat a T2N1 ER 90%, PR 10 %, Her 2 negative Breast cancer in premenopausal women with tumor appearing abutting pectoralis fascia with loss of fat plane with a concern for a positive surgical margin? would you consider neoadjuvant treatment ?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
